Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. (10th February 2020)

• Record Type: Journal Article
• Authors: Kreimer, Aimée R; Sampson, Joshua N; Porras, Carolina; Schiller, John T; Kemp, Troy; Herrero, Rolando; Wagner, Sarah; Boland, Joseph; Schussler, John; Lowy, Douglas R; Chanock, Stephen; Roberson, David; Sierra, Mónica S; Tsang, Sabrina H; Schiffman, Mark; Rodriguez, Ana Cecilia; Cortes, Bernal; Gail, Mitchell H; Hildesheim, Allan; Gonzalez, Paula; Pinto, Ligia A
• Is Part Of: Journal of the National Cancer Institute. Volume 112:Number 10(2020)
• Page Start: 1038
• Page End: 1046
• Publication Date: 2020-02-10
• Subjects: Cancer -- Periodicals; Cancer -- Research -- Periodicals; 616.994
• DOI: 10.1093/jnci/djaa011
• Languages: English
• ISSNs: 0027-8874

Abstract

Abstract: Background: The authors investigated the durability of vaccine efficacy (VE) against human papillomavirus (HPV)16 or 18 infections and antibody response among nonrandomly assigned women who received a single dose of the bivalent HPV vaccine compared with women who received multiple doses and unvaccinated women. Methods: HPV infections were compared between HPV16 or 18-vaccinated women aged 18 to 25 years who received one (N = 112), two (N = 62), or three (N = 1365) doses, and age- and geography-matched unvaccinated women (N = 1783) in the long-term follow-up of the Costa Rica HPV Vaccine Trial. Cervical HPV infections were measured at two study visits, approximately 9 and 11 years after initial HPV vaccination, using National Cancer Institute next-generation sequencing TypeSeq1 assay. VE and 95% confidence intervals (CIs) were estimated. HPV16 or 18 antibody levels were measured in all one- and two-dose women, and a subset of three-dose women, using a virus-like particle-based enzyme-linked immunosorbent assay (n = 448). Results: Median follow-up for the HPV-vaccinated group was 11.3 years (interquartile range = 10.9–11.7 years) and did not vary by dose group. VE against prevalent HPV16 or 18 infection was 80.2% (95% CI = 70.7% to 87.0%) among three-dose, 83.8% (95% CI = 19.5% to 99.2%) among two-dose, and 82.1% (95% CI = 40.2% to 97.0%) among single-dose women. HPV16 or 18 antibody levels did not qualitatively decline between years four and 11 regardless of the number of doses given, although one-dose titers continue to be statistically significantly lower compared with two- and three-dose titers. Conclusion: More than a decade after HPV vaccination, single-dose VE against HPV16 or 18 infection remained high and HPV16 or 18 antibodies remained stable. A single dose of bivalent HPV vaccine may induce sufficiently durable protection that obviates the need for more doses.